$AGTC has seen the biggest fall in its history after making a public offering, followed by today's market performance. The warrants have an exercise price of $0.60 per share.
Applied Genetic Technologies ($AGTC) is a biotechnology company that develops genetic therapies, mostly to restore visual function in people with inherited conditions. Current pipeline consists of 8 candidates.
The company was first introduced to the stock market in 2014, when it went up to $30.46. It established significant collaborations throughout its history, even with companies like Biogen.
Current collaborations include: Bionic Sight, University of Florida, Otonomy, TeamedOn and SparingVision SAS.
What are your thoughts and predictions for this stock?
Leave a Reply